Open access peer-reviewed chapter

Inflammatory Muscle Diseases

Written By

Doris Hissako Sumida, Fernando Yamamoto Chiba and Maria Sara de Lima Coutinho Mattera

Submitted: November 6th, 2018 Reviewed: March 26th, 2019 Published: May 31st, 2019

DOI: 10.5772/intechopen.86053

Chapter metrics overview

876 Chapter Downloads

View Full Metrics


Inflammatory myopathies, also called idiopathic inflammatory myopathy or myositis, are rare conditions characterized by the involvement of various organs in addition to muscle tissue. These changes can lead to severe impairments and adversely impact the quality of life of affected individuals. The diagnosis and treatment of inflammatory myopathies involve the participation of an interdisciplinary team, due to the complexity of the disease and the high variety of possible signs and symptoms. In this chapter we will discuss the epidemiology and characteristics of the main subtypes of inflammatory myopathies, such as polymyositis, dermatomyositis, necrotizing myopathy, overlap myositis, and myositis of inclusion bodies. Next, we will discuss the existence of crosstalk between inflammatory processes in the oral cavity and their consequences on skeletal muscle. As oral inflammation can increase infiltration of macrophages in muscle tissue and this increase is related to the production of proinflammatory cytokines in this tissue, these cytokines can cause muscle weakness. It is important to consider the prevention of chronic inflammatory processes in order to maintain muscle integrity or even prevent the worsening of the clinical condition of patients with inflammatory muscle diseases.


  • myositis
  • dermatomyositis
  • polymyositis
  • inclusion body myositis
  • inflammation

1. Introduction

Inflammatory myopathies, also called idiopathic inflammatory myopathy or myositis, are rare conditions characterized by the involvement of various organs in addition to muscle tissue. These changes can lead to severe impairments and adversely impact the quality of life of affected individuals [1, 2].

The diagnosis and treatment of inflammatory myopathies involve the participation of an interdisciplinary team, due to the complexity of the disease and the high variety of possible signs and symptoms. The integration of subspecialties, such as rheumatologist, neurologist, dermatologist, pulmonologist, cardiologist, and physiotherapist, among others, is necessary to achieve the ideal treatment plan. Diagnosis of inflammatory myopathies involves several steps and often requires autoantibody testing and histological evaluation of a muscle tissue biopsy in addition to several other tests, including muscle magnetic resonance imaging and electromyography. Typical symptoms of inflammatory myopathies include muscle weakness in the arms and legs, which may manifest in a few days or even several weeks. Muscular weakness is reflected in difficulties in performing daily activities such as walking, climbing stairs, or lifting an object above the head. In addition to muscle weakness, it is observed that pain is also a frequent detectable symptom in a patient with inflammatory myopathies. Laboratory tests usually show a significant increase of creatine kinase and elevation in the concentration of liver enzymes that suggest the occurrence of damage to muscle cells [1, 3].

The adverse impact on quality of life highlights the importance of performing an accurate and reliable diagnosis from the combination of clinical and laboratory findings to establish the appropriate treatment for each individual [1, 2].

In this chapter we will discuss the epidemiology and subtypes of inflammatory myopathies. Next, we will discuss the existence of crosstalk between inflammatory processes in the oral cavity and their consequences on skeletal muscle.


2. Inflammatory myopathies

2.1 Epidemiology of inflammatory muscle diseases

All myositis subtypes can be considered rare diseases due to their relatively low prevalence. Studies indicate that overlap myositis represents the subtype of the disease that affects the largest number of people, comprising about half of the cases registered. Dermatomyositis accounts for more than a third of the cases of the disease and presents a prevalence of approximately 1–6 patients per 100,000 people in the United States [4, 5, 6].

It is important to emphasize that obtaining accurate epidemiological data is extremely difficult due to the different diagnostic criteria adopted in each study. Therefore, the information provided by the publications should be examined and evaluated with caution and attention [7].

A large study conducted from the analysis of 3067 patients from Belgium, China, Czech Republic, Hungary, Italy, Mexico, Norway, Sweden, Switzerland, the United Kingdom (UK), and Vietnam who were registered in the Euromyositis Registry demonstrated that the dermatomyositis was the most common disorder with 31% of the cases [7].

Data on the prevalence of necrotizing myopathy suggest that this subtype of the disease accounts for approximately one-fifth of the reported cases of inflammatory muscle diseases [4, 5, 6].

The information regarding the epidemiology of polymyositis varies and depends on the methodology and location of the study ranging from the largest fraction with prevalence of approximately 10 cases per 100,000 people in the United States [1, 2, 3], 27% in the Euromyositis Registry [7], to the rarest subtype that should be diagnosed only by exclusion [4, 5, 6].

Currently there is some consensus that overlap myositis, necrotizing myopathy, and dermatomyositis represent about 90% of the cases of inflammatory muscle diseases [4, 5, 6]. It is estimated that the inclusion body myositis occurs with a prevalence of up to 14 per million people [8].

2.2 Dermatomyositis

Dermatomyositis is typically characterized by the development of proximal muscle weakness and cutaneous manifestations that may arise over a period of weeks to months. However, there are cases in which muscular impairment is not significant without signs and symptoms of muscle weakness, elevated muscle enzymes or changes in electromyography, magnetic resonance imaging (MRI), and muscle biopsy [9].

Skin signs frequently seen in dermatomyositis include an exacerbated periorbital rash with edematous features and erythematous lesions involving the extensor surfaces of the joints. In some cases, myalgia and pruritus may also be observed as important symptoms of the disease. Muscle enzyme concentrations tend to be elevated, and electromyography commonly shows a myopathic pattern [10]. Intramuscular T2 hyperintensities resulting from inflammation or muscle necrosis can be observed on MRI. Dermatomyositis may present a characteristic less frequently observed in other types of inflammatory myopathies, which involves the presence of T2 hyperintensities around individual muscles due to fascial involvement [11].

Muscular biopsies in patients with dermatomyositis have perifascicular atrophy as a feature of high specificity [12]. Evidences show that the expression of perifascicular human myxovirus resistance protein 1 and retinoic acid-inducible gene 1 have higher diagnostic sensitivity than perifascicular atrophy with equivalent specificity [13]. Muscular biopsies of dermatomyositis patients usually present cellular infiltrates composed of plasmacytoid dendritic cells, B cells, CD4 T cells, and macrophages. These cells usually involve medium-sized blood vessels and invade the perimysium [14]. However, it is possible that dermatomyositis biopsy does not present this cellular infiltrate. Predominantly, necrotic pathologically indistinguishable from immune-mediated necrotizing myopathy may be observed. Some early features of dermatomyositis involve deposition of membrane attack complex and presence of microtubular inclusions on intramuscular capillaries [11]. In addition, like other inflammatory myopathies, class-1 major histocompatibility complex (MHC) is generally upregulated in the sarcolemma of muscle fibers. In patients with dermatomyositis, class-1 MHC upregulation and other pathological findings may be characteristically prominent in perifascicular regions [14].

Studies have shown that dermatomyositis autoantibody can be found in a considerable proportion of patients with dermatomyositis [15]. Typical features of dermatomyositis, including proximal muscle weakness and prominent cutaneous manifestations have been associated with the presence of autoantibodies recognizing the nuclear antigen Mi2 [16]. Patients with dermatomyositis and autoantibodies that recognize nuclear matrix protein (NXP) 2 are more predisposed to be affected by proximal and distal muscular weakness, subcutaneous edema, and dysphagia [17].

Patients with dermatomyositis who are positive for anti-NXP2 or anti-transcription intermediary factor (TIF)-1 autoantibodies are at increased risk for malignancy development; thus making comprehensive cancer screening 13–15 or positron emission tomography–computed tomography (PET-CT) scans is extremely important in these cases [18]. In cases of dermatomyositis patients who have autoantibodies recognizing the small ubiquitin-like modifier activating enzyme or melanoma differentiation-associated gene 5 (MDA5), it is observed that cutaneous tissue impairment is more prominent than in muscle. In addition to most commonly present cutaneous manifestations, these patients may develop ulcerous lesions on the flexor surface of the fingers and palm [19, 20].

Most patients with anti-MDA5 autoantibodies are hypomyopathic or amyopathic. In addition, it should be noted that unlike patients with other autoantibodies of dermatomyositis, those who are anti-MDA5 positive often develop an aggressive form of interstitial lung disease, reinforcing the importance of assessment through periodic lung function tests and high-resolution computed tomography [20, 21, 22].

Although the etiology of dermatomyositis is not fully elucidated, it is suggested that a combination of genetic risk factors and exposure to environmental factors may trigger the disease. In this sense, several immunogenetic risk factors, including certain class-2 human leukocyte antigen (HLA) alleles, have been implicated in dermatomyositis pathogenesis [23]. Studies suggest that exposure to ultraviolet light may also be considered an important risk factor for the development of dermatomyositis [24].

Regardless of the origin of dermatomyositis, it is not known which mechanisms are involved in the development of muscle damage and weakness. Studies suggest that muscle damage may result from hypoperfusion due to endothelial destruction [14]. In addition, the presence of plasmacytoid dendritic cells, along with the increase in expression of type-1 interferon-inducible proteins in the perifascicular area, suggests that interferon may mediate perifascicular atrophy [12, 25].

Overlap myositis is being recognized as an individual form of myositis. This myositis manifests itself without a rash typical of dermatomyositis, with prominent pathologic changes in the perifascicular, interfascicular, and perimysial regions, and is frequently associated with anti-synthetase antibodies [2].

Laboratory evaluation shows a significant elevation of muscle enzymes including creatine kinase (CK), which is generally present [3]. Approximately 30% of patients with myositis were positive for Jo-1O antibody (most common of the eight anti-synthetase antibodies) [26].

2.3 Polymyositis

Polymyositis is a rare disease, which belongs to the various idiopathic inflammatory myopathies. It is estimated that the incidence of polymyositis is 5% of all cases of myositis [2, 5, 27]. Polymyositis consists of muscle weakness, elevated creatine phosphokinase concentrations, and myopathic electromyography features [2]. However, rash or other signs of skin inflammation do not occur in polymyositis. Therefore, its diagnosis is by exclusion [3].

Histopathological hallmarks of polymyositis include invasion of endomysial cytotoxic CD8 T cells and widespread upregulation of class I MHC in muscle fibers [2, 24]. Polymyositis is a chronic, degenerative disease that has no cure. The treatment consists in the relief of the symptoms with the use of corticosteroids, such as prednisone, intravenous glucocorticoids (when weakness at onset is severe or rapidly worsening), azathioprine, methotrexate, mycophenolate, cyclosporine, and intravenous immune globulin [3].

2.4 Inclusion body myositis

Inclusion body myositis is a very common disease among inflammatory myopathies affecting mainly men from the age of 50. The disease begins insidiously and develops over a period of years, sometimes asymmetrically; it may begin with unilateral affection of a leg or arm, progress steadily, and lead to deep muscular atrophy [2]. Laboratory evaluation shows that an elevated CK is much blander. Skin changes are not present [3].

There is a higher mortality rate in patients with inclusion body myositis, since muscle weakness (long flexors of the fingers, quadriceps, anterior tibial, and, to a lesser extent, all other muscles of the arms and legs) usually leads to harmful falls and dysphagia can cause aspiration pneumonia [3].

The antibody, identified a few years ago, that is present in inclusion body myositis is cN1A (5NT1A/5NTC1A) [3]. The frequency of this antibody is about 30%; other forms of myositis such as dermatomyositis and other conditions such as Sjögren’s syndrome and systemic lupus erythematosus (SLE) were also positive even in the absence of any muscle symptoms [3, 28, 29]. Study suggested that the presence of cN1A is associated with a more severe course of disease, dysphagia [3, 30], and increased mortality [3, 31]. However, in another study in German patients, the presence of cN1A did not correlate with the severity of dysphagia or muscle impairment [3, 32].

In the histopathological hallmarks, the distribution and the immunophenotypic profile of the inflammatory cells are similar to those seen in polymyositis macrophages and CD8+ T cells which invade nonnecrotic muscle fibers that express MHC class I antigen on the sarcolemma [33], signs of protein accumulation by detection of amyloid (Congo red, thioflavin S, immunohistochemistry for p62 or TDP-43), detection of tubulofilaments on EM, vacuoles and signs of mitochondrial damage as evidenced by histochemical proof of COX-deficient muscle fibers, and paracrystalline inclusions [3, 34, 35].

2.5 Immune-mediated necrotizing myopathy

Immune-mediated necrotizing myopathy is an acute or subacute proximal weakness of the arms and legs, most prominent in the lower limbs [3]. It often affects adults, but it can also occur in children [3]. The progression of the disease is constantly more rapid and severe compared to other myopathies (dermatomyositis and polymyositis) [3]. Laboratory evaluation shows very high muscle enzymes, with an elevated CK of 20–50 times [3]. Neck muscle weakness and dysphagia are common [3].

Approximately 10–20% of patients with immune-mediated necrotizing myopathy have anti-signal recognition particle (SRP); however its detection varies from 0 to 54% [36]. This antibody may be associated with cardiomyopathy and a severe disease with muscle atrophy, interstitial lung disease, and dysphagia [37, 38]. Another antibody that has been identified is reductase (HMGCR) antibody; its detection in certain cohorts was 60% [39].

Histopathological hallmarks in necrotizing myopathy show dispersed necrotic myofibers of varying degrees; moderate and predominantly MHC class I focal regulation, particularly in areas with necrotic fibers; and complement binding to the sarcolemma [2, 3, 40, 41, 42]. Some inflammatory T cells and other immune cells may be present around these focal points, but there are no primary inflammatory lesions. Necrotic fibers typically exhibit a secondary invasion by macrophages to clean the cell debris [3].

2.6 Crosstalk between oral cavity and skeletal muscle

In addition to these inflammatory muscular diseases mentioned above, a localized inflammation at a distance from the skeletal muscle may promote change in this tissue. Recent study proposed the existence of crosstalk between oral cavity and skeletal muscle [43]. The researchers induced oral inflammation in rats and observed that the skeletal muscle was affected by increased infiltration of macrophages, which was suggested by the authors as an explanation for the glucose intolerance shown in animals with oral inflammation [43].

Research conducted over the last 15 years has investigated possible mechanisms that cause changes in macrophages polarization and the effects of these changes on insulin signaling in metabolic organs [44]. These cells exhibit a high degree of functional plasticity, so that the nature of an inflammatory trigger, as well as the cytokines present, can determine their polarization and their functional status [44]. In analogy to the nomenclature T-helper cells (Th), Th1 Th2, macrophages can be classified into two distinct phenotypes: type 1 (M1) classically activated and type 2 (M2) alternatively activated [45].

In vitro, these subsets can be induced by stimulation with interferon gamma (IFN-γ) and lipopolysaccharides (LPS) for M1 or interleukin-4 (IL-4) for M2 [46]. The M1/M2 dichotomy is often used to classify macrophages into pro-inflammatory (M1) or anti-inflammatory (M2) [44]. Among the functions performed by the M1 macrophages, tumor necrosis factor-alpha (TNF-α) production is outstanding [47]. Saghizadeh [48] and collaborators observed that diabetic or insulin-resistant patients have increased expression of TNF-α in skeletal muscle when compared to normoglycemic individuals, suggesting that cytokine plays an important role in the pathogenesis of insulin resistance. TNF-α impairs the insulin signal by decreasing the phosphorylation of insulin receptor substrate 1 (IRS-1) in tyrosine residues [49]. In addition, TNF-α can stimulate some serine kinases including IκB kinase (IKK) and c-Jun amino-terminal kinase (JNK), which promote IRS-1 phosphorylation in serine residues, resulting in insulin signal attenuation [50]. On the other hand, M2 macrophages are associated with tissue repair, angiogenesis, reduction of inflammation, and the improvement of insulin signaling in adipose tissue [45, 51]. In addition to the studies that relate obesity to insulin resistance, there are studies in the literature that demonstrate a correlation between this hormonal resistance and inflammatory processes, such as rheumatoid arthritis and oral inflammations [52, 53, 54]. In this context, the apical periodontitis (AP), an oral inflammation, stands out. AP occurs as a consequence of various aggressions to the dental pulp, including physical, iatrogenic, infectious, and endodontic traumas. This inflammatory picture can cause a wide variety of immunological responses, in order to protect the dental pulp and periapical regions. The regulation of periapical inflammation is extremely complex, as it involves host mediators, including immunological components such as antibodies, cytokines, arachidonic acid metabolites, and neuropeptides [55]. The characteristic inflammatory process of AP presents different types of gram-negative anaerobic bacteria [56] with LPS in the cell wall [57]. Studies have reported that bacteria which are present in the oral cavity can release LPS into the systemic circulation [58]. This substance has the ability to activate toll-like receptors (TLRs), a cell surface receptor that activates innate immunity and induces inflammatory responses. LPS is a specific ligand for TLR2 and TLR4 but has a higher specificity for TLR4 [59, 60]. When released by gram-negative bacteria, LPS binds to a soluble plasma protein called LPS binding protein. LPS or LPS binding protein [61, 62] binds to the CD14 co-receptor via lipopolysaccharide binding protein (LPB), forming the LPS-CD14 complex. This complex, in turn, is recognized by the TLR4-MD-2 complex, present on the cell surface, which is capable of promoting intracellular recruitment of adapter molecules with N-terminal TIR domain, such as myeloid differentiation primary response 88 (MYD88). This molecule can activate the serine kinases JNK and IKKα/β, which promote activation of the activating proteins-1 (AP-1) and factor nuclear kappa B (NF-κB) transcription factors, respectively [63, 64]. NF-κB regulates the expression of several genes involved in different cellular processes such as inflammatory and immune responses and cell growth and development. In the absence of an NF-κB-activating stimulus, this protein is present in the cytoplasm inactive with an inhibitory protein, IκB [65]. Activation of NF-κB can occur not only by exposure of the cells to LPS but also by the action of inflammatory cytokines (TNF-α and IL-1), activation of T and B lymphocytes, UV radiation, and expression of products [66]. After stimulation, the IKK is phosphorylated and activated. The IKK complex consists of two catalytic subunits, IKK-α and IKK-β, in addition to the NF-kappa-B essential modulator (NEMO) or IKK-γ [67]. After activation, IKK recruits and phosphorylates the IκB that is recognized by the ubiquitin ligase machinery, which leads to its polyubiquitination and consequent degradation. In this way, the NF-κB dimers translocate to the nucleus, binding at specific sites of the deoxyribonucleic acid (DNA) and promoting the transcription of a large number of genes [65, 67].

In addition to activating the IKKα/β/NF-κB pathway, TLRs are capable of activating the JNK pathway [68]. The serine/threonine kinase group called JNK (JNK-1, JNK-2, and JNK-3) belongs to the family of mitogen-activated protein kinase (MAPKs), responsible for the regulation of various cellular functions. This regulation occurs largely because of its ability to control the transcription of specific genes by AP-1 [69]. AP-1 is a transcription factor that, when activated, promotes the expression of genes related to innate immunity [70]. In addition to LPS, the signaling pathway of TLRs can be activated by heat shock proteins [71]. Heat shock proteins (HSP) are proteins characterized as chaperones because they have an important function in adaptation to stress and cellular protection, acting mainly in the synthesis and protein degradation, besides regulating fundamental cellular processes [72]. The family of HSPs is divided into subfamilies, classified according to the molecular mass, being small HSPs (8–27 kDa) and large HSPs (100–110 kDa), among which stand out HSP90, HSP70, and HSP60 [73]. In addition to its essential functions as a chaperone [74], HSP70 has an anti-inflammatory effect by inhibiting the activation of NF-KB when present in the intracellular environment [75]. However, stimuli such as cell necrosis and bacterial products such as LPS can cause the passage of HSP70 through the membrane into the extracellular environment [76, 77]. Studies have suggested that elevated serum levels of HSP70 may be correlated with cardiovascular disorder, pulmonary fibrosis, renal damage, oxidative stress, and inflammation [78]. The development of these conditions may occur due to the ability of HSP70 to bind to TLR2 and TLR4, promoting the activation of the NF-κB pathway which, as mentioned above, induces the expression of inflammatory mediators related to insulin resistance [79]. Studies suggest that insulin sensitivity may undergo regulatory action by the adaptive immune system [80, 81]. This system is composed of different types of cells, among which the B and T lymphocytes [82] stand out. T lymphocytes are classified into two main classes: helper T lymphocytes, also known as T helper (Th), and cytotoxic T lymphocytes. The “naïve” Th1 lymphocytes, when interacting with antigen presenting cells, undergo activation and can differentiate into different subtypes [83]. The Th1 subtype expresses proinflammatory cytokines, such as TNF-α and IFN-γ; Th2 expresses mainly anti-inflammatory cytokines, such as interleukin-4 (IL-4) and interleukin-13 (IL-13), and regulatory T cells secrete predominantly anti-inflammatory cytokine and transforming growth factor-β (TGF-β) [84]. Th1 cells play a central role in the recruitment of macrophages and induction of insulin resistance in obesity-induced diabetes models. These effects are counterbalanced by the function of Th2 and Treg cells that maintain an anti-inflammatory state and increase insulin sensitivity [85]. Appropriate regulation of Th cells is of extreme importance for the control and prevention of various diseases [86]. An increase or decrease in the Th1 or Th2 subtypes, as well as the cytokines produced by these cells, indicates an imbalance that may be one of the factors responsible for the development of insulin resistance [87]. It is known that insulin resistance is one of the main characteristics of diabetes mellitus [88]. This disease is also closely related to muscle weakness due to altered insulin action [89], standing out that insulin is an important anabolic hormone for protein metabolism [90].

The study performed by Boon et al. [91] with healthy lean individuals observed that only 5 days of hyperlipidic diet promoted increased messenger ribonucleic acid (mRNA) expression of macrophage markers in skeletal muscle and reduced expression of the glucose transporter type 4 (GLUT-4) glucose transporter protein in this tissue. Similarly, Patsouris et al. [92] demonstrated increased macrophage content in skeletal muscle in diabetic patients independently of body mass index (BMI). An increased macrophage content (assessed by F4/80 protein detection) was observed in muscle tissue of rats with AP in the absence of obesity, highlighting the key role of these cells in the etiology of insulin resistance. It should be noted that only F4/80 detection is not able to provide details on M1-type and M2-type macrophage polarization although evidence demonstrates that under obesity conditions, macrophages infiltrated into muscle tissue exhibit phenotype characteristic of M1 polarization [92, 93, 94, 95]. The reprogramming of the M1 polarization toward the M2 polarization may represent a promising strategy for the treatment of glycemic homeostasis in patients with diabetes and insulin resistance [44].

As previously reported, inflammation causes insulin resistance. According to Pereira et al., rats with AP had increased IKKα/β and JNK phosphorylation status in gastrocnemius muscle. These results are in agreement with the study of Yaspelkis et al. [96], who observed a higher IKKα/β phosphorylation status in the skeletal muscle of rats treated with a hyperlipidic diet for 12 weeks, and also the study by Todd et al. [97] that identified an increase in JNK activity in the skeletal muscle of rats subjected to 3 weeks of hyperlipidic diet. Kaneto et al. [98] reported that treatment of diabetic rats with JNK inhibitors improved the insulin sensitivity of the animals. Similarly, studies by Yuan et al. [99] and Hundal et al. [100] have reported that inhibition of IKK-β by the administration of salicylates improves insulin action in obese and diabetic human and rats. Furthermore, it has been demonstrated that genetically modified mice, which do not express IKK-β or JNK, are protected from obesity-induced insulin resistance [99, 101, 102, 103].

In addition to stimulating inhibitory effects on insulin signal transduction, TNF-α may interact with tumor necrosis factor receptor 1 (TNFR1) in skeletal muscle [104] and thereby stimulate the NF-κB and/or MAPK pathway [105, 106], which are related to the phosphorylation of IKK and JNK and, in their turn, may impair insulin action. Pereira et al. [43] evaluated the plasma concentrations of LPS and HSP70 in AP models. Rats with AP showed a significant increase in both LPS and HSP70 when compared to the control group. Research on diabetes suggests that chronic elevation of LPS levels may play a key role in the development of insulin resistance [107, 108].

Among the possible mechanisms involved in this alteration, we highlight the ability of LPS to bind to the TLR4 receptor, which may trigger the activation of inflammatory signaling pathways related to inhibition of the insulin signal [108]. Another mediator that plays an active role in the modulation of inflammation is the heat shock proteins. The study by Goodman et al. [109] reported higher expression of 44 HSP genes in periapical granulomas compared to healthy periodontal tissues. Elevation of HSP70 plasma concentrations observed in rats with AP may indicate that increased local HSP expression is associated with higher concentrations of this protein in serum [43]. Interestingly, studies have shown that serum concentrations of HSP70 are higher in diabetic patients [110, 111]. Asea et al. [79] reported that HSP70 can bind to the TLR4 receptor, suggesting a possible involvement of this protein in the development of insulin resistance. With regard to the adaptive immunity markers, animals from the AP groups showed an increase in the Th1 response represented by increased T-bet expression in the spleen and elevated plasma concentrations of INF-γ [43]. A study carried out with knockout animals for the T-bet gene treated with hypercaloric diet showed that even with weight gain and increased adiposity, the animals were protected from insulin resistance [112]. The authors attributed the lack of insulin resistance to reduced production of INF-γ. These results are consistent with studies that reported that IFN-γ deficiency may improve glycemic homeostasis under obesity conditions [113, 114, 115]. In addition, treatment of adipocytes (3 T3-L1) with interferon gamma (INF-γ) reduces insulin signal and glucose uptake [116]. The functions of Th1 cells are antagonized by the Th2 subpopulation presenting the transcription factor GATA3 and IL-4 as specific markers. The AP in rats promotes a reduction of IL-4 [43]. Chang et al. [117] reported that IL-4 treatment promotes improved insulin sensitivity and glucose tolerance and simultaneously reduces body weight in obese rats. These findings suggest that IL-4 plays beneficial effects on glycemic homeostasis. The role of Th2 cells in insulin sensitivity was demonstrated in the study by Gonzales et al. [118]. In this study, a model of inactivation of Th2 response was developed through the inhibition of the activator of transcription 6 (STAT6) protein, in which it was observed that animals with Th2 response deficiency were more prone to insulin resistance. Thus, the reduction of the Th2 response observed in rats with AP may contribute to the understanding of the mechanisms involved in insulin resistance observed in animals with AP [43, 54].

Studies suggest that TNF-α contributes to age-related muscle loss and that resistance exercise may attenuate this process by suppressing TNF-α expression in skeletal muscle [119]. Other findings demonstrate that decreased muscle strength in diabetic individuals is associated with elevated plasma concentrations of TNF-α and interleukin-6 (IL-6) [120]. Therefore, considering that oral inflammation, such as AP, may increase infiltration of macrophages in muscle tissue and this increase is related to the production of proinflammatory cytokines, it is possible to suggest that prevention of chronic inflammatory oral diseases contributes to the maintenance of muscle integrity.


3. Conclusions

The main subtypes of inflammatory muscular diseases are polymyositis, dermatomyositis, necrotizing myopathy, overlap myositis, and myositis of inclusion bodies. The origin of these diseases is idiopathic, making it difficult to prevent them. As oral inflammation can increase infiltration of macrophages in muscle tissue and this increase is related to the production of proinflammatory cytokines in this tissue, these cytokines can cause muscle weakness. It is important to consider the prevention of chronic inflammatory processes in order to maintain muscle integrity or even prevent the worsening of the clinical condition of patients with inflammatory muscle diseases.


Conflict of interest

The authors declare that there are no conflicts of interest.



This study was supported by the São Paulo Research Foundation (FAPESP) [grant #2016/24829-2] São Paulo, SP, Brazil.


Appendices and nomenclature


apical periodontitis


activating proteins-1


body mass index


cluster of differentiation 14


cluster of differentiation 4


cluster of differentiation 8


creatine kinase




deoxyribonucleic acid


glucose transporter type 4


human leukocyte antigen


3-hydroxy-3-methylglutaryl-CoA reductase


heat shock proteins


interferon gamma


IkB kinase








insulin resistance


insulin receptor substrate 1


c-jun amino-terminal kinase


lipopolysaccharide binding protein




M1-type macrophage polarization


M2-type macrophage polarization


mitogen-activated protein kinase


melanoma differentiation-associated gene 5


major histocompatibility complex


magnetic resonance imaging


messenger ribonucleic acid


myeloid differentiation primary response 88


NF-kappa-B essential modulator


factor nuclear kappa B


nuclear matrix protein


positron emission tomography–computed tomography


systemic lupus erythematosus


signal recognition particle


activator of transcription 6


transactive DNA-binding protein 43


transforming growth factor-β




transcription intermediary factor


toll-like receptors


tumor necrosis factor receptor 1


tumor necrosis factor-alpha


United Kingdom


United States of America


  1. 1. Carstens PO, Schmidt J. Diagnosis, pathogenesis and treatment of myositis: Recent advances. Clinical and Experimental Immunology. 2014;175:349-358. DOI: 10.1111/cei.12194
  2. 2. Dalakas MC. Inflammatory muscle diseases. The New England Journal of Medicine. 2015;372:1734-1747. DOI: 10.1056/NEJMra1402225
  3. 3. Schmidt J. Current classification and management of inflammatory myopathies. Journal of Neuromuscular Diseases. 2018;5:109-129. DOI: 10.3233/JND-180308
  4. 4. Furst DE, Amato AA, Iorga Ş, Gajria K, Fernandes AW. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle & Nerve. 2012;45:676-683. DOI: 10.1002/mus.23302
  5. 5. Senécal JL, Raynauld JP, Troyanov Y. Editorial: A new classification of adult autoimmune myositis. Arthritis & Rhematology. 2017;69:878-884. DOI: 10.1002/art.40063
  6. 6. Van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, et al. Polymyositis: An overdiagnosed entity. Neurology. 2003;61:316-321. DOI: 10.1212/WNL.61.3.316
  7. 7. Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, et al. The EuroMyositis registry: An international collaborative tool to facilitate myositis research. Annals of the Rheumatic Diseases. 2018;77:30-39. DOI: 10.1136/annrheumdis-2017-211868
  8. 8. Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia FL. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. Journal of Clinical Neuroscience. 2008;15:1350-1353. DOI: 10.1016/j.jocn.2008.01.011
  9. 9. Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurology. 2018;17:816-828. DOI: 10.1016/S1474-4422(18)30254-0
  10. 10. Paganoni S, Amato A. Electrodiagnostic evaluation of myopathies. Physical Medicine and Rehabilitation Clinics of North America. 2013;24:193-207. DOI: 10.1016/j.pmr.2012.08.017
  11. 11. Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, Lahouti AH, Basharat P, Albayda J, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: Extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Annals of the Rheumatic Diseases. 2017;76:1-7. DOI: 10.1136/annrheumdis-2016-210198
  12. 12. Suárez-Calvet X, Gallardo E, Pinal-Fernandez I, De Luna N, Lleixà C, Díaz-Manera J, et al. RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis. Arthritis Research & Therapy. 2017;19:174. DOI: 10.1186/s13075-017-1383-0
  13. 13. Uruha A, Nishikawa A, Tsuburaya RS, Hamanaka K, Kuwana M, Watanabe Y, et al. Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. Neurology. 2017;88:493-500. DOI: 10.1212/WNL.0000000000003568
  14. 14. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheumatic Diseases Clinics of North America. 2002;28:779-798. DOI: 10.1016/S0889-857X (02)00030-3
  15. 15. Betteridge Z, McHugh N. Myositis-specific autoantibodies: An important tool to support diagnosis of myositis. Journal of Internal Medicine. 2016;280:8-23. DOI: 10.1111/joim.12451
  16. 16. Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, et al. Anti-Mi-2 antibodies. Autoimmunity. 2005;38:79-83. DOI: 10.1080/08916930400022681
  17. 17. Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care & Research. 2017;69:1771-1776. DOI: 10.1002/acr.23188
  18. 18. Selva-O’Callaghan A, Grau JM, Gamez-Cenzano C, Vidaller-Palacin A, Martinez-Gomez X, Trallero-Araguas E, et al. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. The American Journal of Medicine. 2010;123:558-562. DOI: 10.1016/j.amjmed.2009.11.012
  19. 19. Ge Y, Lu X, Shu X, Peng Q , Wang G. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Scientific Reports. 2017;7:188. DOI: 10.1038/s41598-017-00240-6
  20. 20. Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous ulceration in dermatomyositis: Association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care & Research. 2015;67:667-672. DOI: 10.1002/acr.22498
  21. 21. Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. Journal of Immunology Research. 2014;2014:290-797. DOI: 10.1155/2014/290797
  22. 22. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis and Rheumatism. 2009;60:2193-2200. DOI: 10.1002/art.24621
  23. 23. Miller FW, Chen W, O'Hanlon TP, Cooper RG, Vencovsky J, Rider LG, et al. Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes and Immunity. 2015;16:470-480. DOI: 10.1038/gene.2015.28
  24. 24. Mamyrova G, Rider LG, Ehrlich A, Jones O, Pachman LM, Nickeson R, et al. Environmental factors associated with disease flare in juvenile and adult dermatomyositis. Rheumatology. 2017;56:1342-1347. DOI: 10.1093/rheumatology/kex162
  25. 25. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Annals of Neurology. 2005;57:664-678. DOI: 10.1002/ana.20464
  26. 26. Lega JC, Fabien N, Reynaud Q , Durieu I, Durupt S, Dutertre M, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: A meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmunity Reviews. 2014;13:883-891. DOI: 10.1016/j.autrev.2014.03.004
  27. 27. Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Current Opinion in Neurology. 2016;29:662-673. DOI: 10.1097/WCO.0000000000000376
  28. 28. Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, Tiniakou E, Petri M, Baer A, et al. Cytosolic 5’-nucleotidase 1A As a target of circulating autoantibodies in autoimmune diseases. Arthritis Care & Research. 2016;68:66-71. DOI: 10.1002/acr.22600
  29. 29. Herbert MK, Stammen-Vogelzangs J, Verbeek MM, Rietveld A, Lundberg IE, Chinoy H, et al. Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Annals of the Rheumatic Diseases. 2016;75:696-701. DOI: 10.1136/annrheumdis-2014-206691
  30. 30. Goyal NA, Cash TM, Alam U, Enam S, Tierney P, Araujo N, et al. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. Journal of Neurology, Neurosurgery, and Psychiatry. 2016;87:373-378. DOI: 10.1136/jnnp-2014-310008
  31. 31. Lilleker JB, Rietveld A, Pye SR, Mariampillai K, Benveniste O, Peeters MT, et al. Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Annals of the Rheumatic Diseases. 2017;76:862-868. DOI: 10.1136/annrheumdis-2016-210282
  32. 32. Olthoff A, Carstens PO, Zhang S, von FE, Friede T, Lotz J, et al. Evaluation of dysphagia by novel real-time MRI. Neurology. 2016;87:2132-2138. DOI: 10.1212/WNL.0000000000003337
  33. 33. Vattemi G, Mirabella M, Guglielmi V, Lucchini M, Tomelleri G, Ghirardello A, et al. Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis. Autoimmunity Highlights. 2014;5:77-85. DOI: 10.1007/s13317-014-0062-2
  34. 34. Ikenaga C, Kubota A, Kadoya M, Taira K, Uchio N, Hida A, et al. Clinicopathologic features of myositis patients with CD8-MHC-1 complex pathology. Neurology. 2017;89:1060-1068. DOI: 10.1212/WNL.0000000000004333
  35. 35. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008;70:418-424. DOI: 10.1212/01.wnl.0000277527.69388.fe
  36. 36. Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKA. Comprehensive overview on myositis-specific antibodies: New and old biomarkers in idiopathic inflammatory myopathy. Clinical Reviews in Allergy and Immunology. 2017;52:1-19. DOI: 10.1007/s12016-015-8510-y
  37. 37. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis and Rheumatism. 1990;33:1361-1370. DOI: 10.1002/art.1780330908
  38. 38. Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: Case series of 100 patients. Orphanet Journal of Rare Diseases. 2015;10:61. DOI: 10.1186/s13023-015-0277-y
  39. 39. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis and Rheumatism. 2010;62:2757-2766. DOI: 10.1002/art.27572
  40. 40. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscular Disorders. 2004;14:337-345. DOI: 10.1016/j.nmd.2004.02.006
  41. 41. Allenbach Y, Benveniste O, Goebel HH, Stenzel W. Integrated classification of inflammatory myopathies. Neuropathology and Applied Neurobiology. 2017;43:62-81. DOI: 10.1111/nan.12380
  42. 42. Stenzel W, Goebel HH, Aronica E. Review: Immune-mediated necrotizing myopathies–a heterogeneous group of diseases with specific myopathological features. Neuropathology and Applied Neurobiology. 2012;38:632-646. DOI: 10.1111/j.1365-2990.2012.01302.x
  43. 43. Pereira RF, Cintra LTA, Tessarin GWL, Chiba FY, de Lima Coutinho Mattera MS, Scaramele NF, et al. Periapical lesions increase macrophage infiltration and inflammatory signaling in muscle tissue of rats. Journal of Endodontia. 2017;43:982-988. DOI: 10.1016/j.joen.2017.01.030
  44. 44. Lauterbach MA, Wunderlich FT. Macrophage function in obesity-induced inflammation and insulin resistance. Pflügers Archiv. 2017;469:385-396. DOI: 10.1007/s00424-017-1955-5
  45. 45. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. The Journal of Clinical Investigation. 2007;117:175-184. DOI: 10.1172/JCI29881
  46. 46. Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nature Immunology. 2016;17:39-40. DOI: 10.1038/ni.3324
  47. 47. Metzger Z. Macrophages in periapical lesions. Endodontics & Dental Traumatology. 2000;16:1-8
  48. 48. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF a by human muscle. The Journal of Clinical Investigation. 1996;97:1111-1116. DOI: 10.1172/JCI118504
  49. 49. Hotamisligil GS. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271:665-658. DOI: 10.1126/science.271.5249.665
  50. 50. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nature Medicine. 2012;18:363-374. DOI: 10.1038/nm.2627
  51. 51. Nguyen KD, Qiu Y, Cui X, Goh YP, Mwangi J, David T, et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature. 2011;20:104-108. DOI: 10.1038/nature10653
  52. 52. Silber SJ. Apparent fertility of human spermatozoa from the caput epididymitis. Journal of Andrology. 1989;4:263-269. DOI: 10.1002/j.1939-4640.1989.tb00098.x
  53. 53. Giles JT, Danielides S, Szklo M, Post WS, Blumenthal RS, Petri M, et al. Insulin resistance in rheumatoid arthritis: Disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis & Rhematology. 2015;67:626-636. DOI: 10.1002/art.38986
  54. 54. Astolphi RD, Curbete MM, Colombo NH, Shirakashi DJ, Chiba FY, Prieto AK, et al. Periapical lesions decrease insulin signal and cause insulin resistance. Journal of Endodontia. 2013;39:648-652. DOI: 10.1016/j.joen.2012.12.031
  55. 55. Stashenko P, Teles R, D'Souza R. Periapical inflammatory responses and their modulation. Critical Reviews in Oral Biology and Medicine. 1998;9:498-521. DOI: 10.1177/10454411980090040701
  56. 56. Sundqvist G. Ecology of the root canal flora. Journal of Endodontia. 1992;18:427-430. DOI: 10.1016/S0099-2399(06)80842-3
  57. 57. Wolff SM. Biological effects of bacterial endotoxins in man. The Journal of Infectious Diseases. 1973;128:259-264. DOI: 10.1093/infdis/128.Supplement_1.S259
  58. 58. Geerts SO, Nys M, De MP, Charpentier J, Albert A, Legrand V, et al. Systemic release of endotoxins induced by gentle mastication: Association with periodontitis severity. Journal of Periodontology. 2002;73:73-78. DOI: 10.1902/jop.2002.73.1.73
  59. 59. Medzhitov R. Toll-like receptors and innate immunity. Nature Reviews Immunology. 2001;1:135-145. DOI: 10.1038/35100529
  60. 60. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, et al. Cutting edge: Role of toll-like receptor 1 in mediating immune response to microbial lipoproteins. Journal of Immunology. 2002;169:10-14. DOI: 10.4049/jimmunol.169.1.10
  61. 61. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C2H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science. 1998;282:2085-2088. DOI: 10.1126/science.282.5396.2085
  62. 62. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783-801. DOI: 10.1016/j.cell.2006.02.015
  63. 63. Ohnishi T, Muroi M, Tanamoto K. The lipopolysaccharide-recognition mechanism in cells expressing TLR4 and CD14 but lacking MD-2. FEMS Immunology and Medical Microbiology. 2007;51:84-91. DOI: 10.1111/j.1574-695X.2007.00281.x
  64. 64. Pålsson-McDermott EM, O'Neill LA. Signal transduction by the lipopolysaccharide receptor, toll-like receptor-4. Immunology. 2004;113:153-162. DOI: 10.1111/j.1365-2567.2004.01976.x
  65. 65. Napetschnig J, Wu H. Molecular basis of NF-κB signaling. Annual Review of Biophysics. 2013;42:443-468. DOI: 10.1146/annurev-biophys-083012-130338
  66. 66. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: New discoveries and insights. Annual Review of Immunology. 1996;14:649-683. DOI: 10.1146/annurev.immunol.14.1.649
  67. 67. Li Q , Verma IM. NF-kb regulation in the immune system. Nature Reviews. Immunology. 2002;12:975. DOI: 10.1038/nri910
  68. 68. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. The Journal of Clinical Investigation. 2006;116:1793-1801. DOI: 10.1172/JCI29069
  69. 69. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. The Journal of Clinical Investigation. 2005;115:1111-1119. DOI: 10.1172/JCI25102
  70. 70. Bennett BL, Satoh Y, Lewis AJ. JNK: A new therapeutic target for diabetes. Current Opinion in Pharmacology. 2003;3:420-425. DOI: 10.1016/S1471-4892(03)00068-7
  71. 71. Fang H, Wu Y, Huang X, Wang W, Ang B, Cao X, et al. Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response. The Journal of Biological Chemistry. 2011;286:30393-30400. DOI: 10.1074/jbc.M111.266528
  72. 72. Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausei S, Boni L, et al. The role of heat shock proteins in câncer. Cancer Letters. 2015;360:114-118. DOI: 10.1016/j.canlet.2015.02.026
  73. 73. Lindquist S, Craig EA. The heat shock proteins. Annual Review of Genetics. 1988;22:631-637
  74. 74. Pilon M, Schekman R. Protein translocation: How Hsp70 pulls it off. Cell. 1999;97:679-682. DOI: 10.1016/S0092-8674(00)80780-1
  75. 75. Heck TG, Schöler CM, de Bittencourt PI. HSP70 expression: Does it a novel fatigue signalling factor from immune system to the brain? Cell Biochemistry and Function. 2011;29:215-226. DOI: 10.1002/cbf.1739
  76. 76. Davies EL, Bacelar MM, Marshall MJ, Johnson E, Wardle TD, Andrew SM, et al. Heat shock proteins form part of a danger signal cascade in response to lipopolysaccharide and GroEL. Clinical and Experimental Immunology. 2006;145:183-189. DOI: 10.1111/j.1365-2249.2006.03109.x
  77. 77. Mambula SS, Stevenson MA, Ogawa K, Calderwood SK. Mechanisms for Hsp70 secretion: Crossing membranes without a leader. Methods. 2007;43:168-175. DOI: 10.1016/j.ymeth.2007.06.009
  78. 78. Ogawa F, Shimizu K, Hara T, Muroi E, Hasegawa M, Takehara K, et al. Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: Association with fibrosis and vascular damage. Clinical and Experimental Rheumatology. 2008;26:659-662
  79. 79. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, et al. Novel signal transduction pathway utilized by extracellular HSP70: Role of toll-like receptor (TLR)2 and TLR4. The Journal of Biological Chemistry. 26 Apr 2002;277(17):15028-15034. DOI: 10.1074/jbc.M200497200
  80. 80. Bronsart LL, Contag CH. A role of the adaptive immune system in glucose homeostasis. BMJ Open Diabetes Research & Care. 2016;4:e000136. DOI: 10.1136/bmjdrc-2015-000136
  81. 81. Winer S, Winer DA. The adaptive immune system as a fundamental regulator of adipose tissue inflammation and insulin resistance. Immunology and Cell Biology. 2012;90:755-762. DOI: 10.1038/icb.2011.110
  82. 82. Corthay A. How do regulatory T cells work. Scandinavian Journal of Immunology. 2009;70:326-336. DOI: 10.1111/j.1365-3083.2009.02308.x
  83. 83. Antignano F, Zaph C. Regulation of CD4 T-cell differentiation and inflammation by repressive histone methylation. Immunology and Cell Biology. 2015;93:245-252. DOI: 10.1038/icb.2014.115
  84. 84. Hansson GK. Atherosclerosis-an immune disease: The anitschkov lecture 2007. Atherosclerosis. 2009;202:2-10. DOI: 10.1016/j.atherosclerosis.2008.08.039
  85. 85. Wali JA, Thomas HE, Sutherland AP. Linking obesity with type 2 diabetes: The role of T-bet. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2014;7:331-340. DOI: 10.2147/DMSO.S51432
  86. 86. Zhao G, Zhou S, Davie A, Su Q. Effects of moderate and high intensity exercise on T1/T2 balance. Exercise Immunology Review. 2012;18:98-114
  87. 87. Deiuliis J, Shah Z, Shah N, Needleman B, Mikami D, Narula V, et al. Visceral adipose inflammation in obesity is associated with critical alterations in T regulatory cell numbers. PLoS One. 2011;6:16376. DOI: 10.1371/journal.pone.0016376
  88. 88. Taylor R. Insulin resistance and type 2 diabetes. Diabetes. 2012;61:778-779. DOI: 10.2337/db12-0073
  89. 89. Perry BD, Caldow MK, Brennan-Speranzam TC, Sbaraglia M, Jerums G, Garnham A, et al. Muscle atrophy in patients with type 2 diabetes mellitus: Roles of inflammatory pathways, physical activity and exercise. Exercise Immunology Review. 2016;22:94-108
  90. 90. Qaid MM, Abdelrahman MM. Role of insulin and other related hormones in energy metabolism—A review. Cogent Food & Agriculture. 2016;2:1267691. DOI: 10.1080/23311932.2016.1267691
  91. 91. Boon MR, Bakker LE, Haks MC, Quinten E, Schaart G, Van Beek L, et al. Short-term high-fat diet increases macrophage markers in skeletal muscle accompanied by impaired insulin signalling in healthy male subjects. Clinical Science. 2015;128:143-151. DOI: 10.1042/CS20140179
  92. 92. Patsouris D, Cao JJ, Vial G, Bravard A, Lefai E, Durand A, et al. Insulin resistance is associated with MCP1-mediated macrophage accumulation in skeletal muscle in mice and humans. PLoS One. 2014;9:110-653. DOI: 10.1371/journal.pone.0110653
  93. 93. Fink LN, Costford SR, Lee YS, Jensen TE, Bilan PJ, Oberbach A, et al. Pro-inflammatory macrophages increase in skeletal muscle of high fat-fed mice and correlate with metabolic risk markers in humans. Obesity. 2014;22:747-757. DOI: 10.1002/oby.20615
  94. 94. Khan IM, Perrard XY, Brunner G, Lui H, Sparks LM, Smith SR, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. International Journal of Obesity. 2015;39:1607-1618. DOI: 10.1038/ijo.2015.104
  95. 95. Wu H, Ballantyne CM. Skeletal muscle inflammation and insulin resistance in obesity. The Journal of Clinical Investigation. 2017;127:43-54. DOI: 10.1172/JCI88880
  96. 96. Yaspelkis BB 3rd, Kvasha IA, Figueroa TY. High-fat feeding increases insulin receptor and IRS-1 coimmunoprecipitation with SOCS-3, IKKalpha/beta phosphorylation and decreases PI-3 kinase activity in muscle. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2009;296:1709-1715. DOI: 10.1152/ajpregu.00117.2009
  97. 97. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nature Genetics. 2007;39:857-864. DOI: 10.1038/ng2068
  98. 98. Kaneto H, Nakatani Y, Kawamori D, Miyatsuka T, Matsuoka TA. Involvement of oxidative stress and the JNK pathway in glucose toxicity. Nature Medicine. 2004;1:165-174. DOI: 10.1900/RDS.2004.1.165
  99. 99. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293:1673-1677. DOI: 10.1126/science.1061620
  100. 100. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. The Journal of Clinical Investigation. 2002;109:1321-1326. DOI: 10.1172/JCI14955
  101. 101. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, et al. Prevention of fat-induced insulin resistance by salicylate. The Journal of Clinical Investigation. 2001;108:37-46. DOI: 10.1172/JCI11559
  102. 102. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420:333-336. DOI: 10.1038/nature01137
  103. 103. Singh R, Wang Y, Xiang Y, Tanaka KE, Gaarde WA, Czaja MJ. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology. 2009;49:87-96. DOI: 10.1002/hep.22578
  104. 104. Hardin BJ, Campbell KS, Smith JD, Arbogast S, Smith J, Moylan JS, et al. TNF-alpha acts via TNFR1 and muscle-derived oxidants to depress myofibrillar force in murine skeletal muscle. Journal of Applied Physiology. 2008;104:694-699. DOI: 10.1152/japplphysiol.00898.2007
  105. 105. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacology & Therapeutics. 2008;117:244-279. DOI: 10.1016/j.pharmthera.2007.10.001
  106. 106. Aggarwal BB. Signalling pathways of the TNF superfamily: A double-edged sword. Nature Reviews. Immunology. 2003;3:745-775. DOI: 10.1038/nri1184
  107. 107. Watanabe K, Iizuka T, Adeleke A, Pham L, Shlimon AE, Yasin M, et al. Involvement of toll-like receptor 4 in alveolar bone loss and glucose homeostasis in experimental periodontitis. Journal of Periodontology. 2011;46:21-30. DOI: 10.1111/j.1600-0765.2010.01304.x
  108. 108. Liang H, Hussey SE, Sanchez-Avila A, Tantiwong P, Musi N. Effect of lipopolysaccharide on inflammation and insulin action in human muscle. PLoS One. 2013;8:e63983. DOI: 10.1371/journal.pone.0063983
  109. 109. Goodman SC, Letra A, Dorn S, Araujo-Pires AC, Vieira AE, Chaves de Souza L, et al. Expression of heat shock proteins in periapical granulomas. Journal of Endodontia. 2014;40:830-836. DOI: 10.1016/j.joen.2013.10.021
  110. 110. Nakhjavani M, Morteza A, Esteghamati A, Khalilzadeh O, Zandieh A, Safari R. Serum lipoprotein(a) levels are greater in female than male patients with type-2 diabetes. Lipids. 2011;46:349-356. DOI: 10.1007/s11745-010-3513-1
  111. 111. Hunter-Lavin C, Hudson PR, Mukherjee S, Davies GK, Williams CP, Harvey JN, et al. Folate supplementation reduces serum hsp70 levels in patients with type 2 diabetes. Cell Stress & Chaperones. 2004;9:344-349. DOI: 10.1379/CSC-28R.1
  112. 112. Stolarczyk E, Lord GM, Howard JK. The immune cell transcription factor T-bet: A novel metabolic regulator. Adipocytes. 2013;3:58-62. DOI: 10.4161/adip.26220
  113. 113. Rocha VZ, Folco EJ, Sukhova G, Shimizu K, Gotsman I, Vernon AH, et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: A role for adaptive immunity in obesity. Circulation Research. 2008;103:467-476. DOI: 10.1161/CIRCRESAHA.108.177105
  114. 114. Wright BL, Nguyen N, Shim KP, Masterson JC, Jacobsen EA, Ochkur SI, et al. Increased GATA-3 and T-bet expression in eosinophilic esophagitis versus gastroesophageal reflux disease. The Journal of Allergy and Clinical Immunology. 2018;141:1919-1921. DOI: 10.1016/j.jaci.2017.12.993
  115. 115. O’Rourke RW, White AE, Metcalf MD, Winters BR, Diggs BS, Zhu X, et al. Systemic inflammation and insulin sensitivity in obese IFN-γ knockout mice. Metabolism. 2012;61:1152-1161. DOI: 10.1016/j.metabol.2012.01.018
  116. 116. Wada T, Hoshino M, Kimura Y, Ojima M, Nakano T, Koya D, et al. Both type I and II IFN induce insulin resistance by inducing different isoforms of SOCS expression in 3T3-L1 adipocytes. American Journal of Physiology. Endocrinology and Metabolism. 2011;300:1112-1123. DOI: 10.1152/ajpendo.00370.2010
  117. 117. Chang YH, Ho KT, Lu SH, Huang CN, Shiau MY. Regulation of glucose/lipid metabolism and insulin sensitivity by interleukin-4. International Journal of Obesity. 2012;36:993-998. DOI: 10.1038/ijo.2011.168
  118. 118. Ricardo-Gonzalez RR, Red Eagle A, Odegaard JI, Jouihan H, Morel CR, Heredia JE, et al. IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:22617-22622. DOI: 10.1073/pnas.1009152108
  119. 119. Greiwe JS, Cheng B, Rubin DC, Yarasheski KE, Semenkovich CF. Resistance exercise decreases skeletal muscle tumor necrosis factor alpha in frail elderly humans. The FASEB Journal. 2001;15:475-482. DOI: 10.1096/fj.00-0274com
  120. 120. Ferreira JP, Leal AMO, Vasilceac FA, Sartor CD, Sacco ICN, Soares AS, et al. Decreased muscle strength is associated with proinflammatory cytokines but not testosterone levels in men with diabetes. Brazilian Journal of Medical and Biological Research. 2018;51:7394. DOI: 10.1590/1414-431X20187394

Written By

Doris Hissako Sumida, Fernando Yamamoto Chiba and Maria Sara de Lima Coutinho Mattera

Submitted: November 6th, 2018 Reviewed: March 26th, 2019 Published: May 31st, 2019